key: cord-0746497-33g2xvvr
authors: Casas-Sanchez, Aitor; Romero-Ramirez, Alessandra; Hargreaves, Eleanor; Ellis, Cameron C.; Grajeda, Brian I.; Estevao, Igor; Patterson, Edward I.; Hughes, Grant L.; Almeida, Igor C.; Zech, Tobias; Acosta-Serrano, Álvaro
title: Protein N-glycosylation is essential for SARS-CoV-2 infection
date: 2021-06-04
journal: bioRxiv
DOI: 10.1101/2021.02.05.429940
sha: c71e4048d4358f60e43ae590e6f11886b5945189
doc_id: 746497
cord_uid: 33g2xvvr

SARS-CoV-2 extensively N-glycosylates its spike proteins, which are necessary for host cell invasion and the target of both vaccines and immunotherapies. These sugars are predicted to help mediate spike binding to the host receptor by stabilizing its ‘open’ conformation and evading host immunity. Here, we investigated both the essentiality of the host N-glycosylation pathway and SARS-CoV-2 N-glycans for infection. Inhibition of host N-glycosylation using RNAi or FDA-approved drugs reduced virus infectivity, including that of several variants. Under these conditions, cells produced less virions and some completely lost their infectivity. Furthermore, partial deglycosylation of intact virions showed that surface-exposed N-glycans are critical for cell invasion. Altogether, spike N-glycosylation is a targetable pathway with clinical potential for treatment or prevention of COVID-19.

enzymes throughout the pathway may also promote protection against infection. We 135 tested several compounds known to inhibit important N-glycosylation steps, at 136 concentrations considered to be at a low or high end of the effective range (Fig. 1A) . 137

To emulate the effects of siSTT3 knocking down the early pathway, we used 138 tunicamycin -to block formation of the N-glycan intermediate phosphate-and NGI-1 that inhibits STT3 directly. Further down in the pathway as in 140 siGANAB, we inhibited the ER a-glucosidase I and II using iminosugars 1-141 deoxynojirimycin (DNJ), Miglitol(22) , ), N-142 Nonyldeoxynojirimycin (NN-DNJ), Celgosivir(24) and Acarbose (25) . Late in the 143 pathway and resembling siMGAT1, we tested the efficacy of Deoxymannojirimycin 144 (DMJ) and Swainsonine to inhibit the Golgi a-mannosidases I and II, respectively. Pre-145 incubation of both Vero and HEK cells with most inhibitors prior to SARS-CoV-2 146 inoculation resulted in a significant reduction in infection compared to untreated cells 147 ( Fig. 2 , A to C). Importantly, NGI-1, Miglustat and Celgosivir were equally effective at 148 reducing the infection in either Vero and HEK cells by SARS-CoV-2 variants B.1.1.7 149 (UK), B.1.351 (South Africa) and P.1 (Brazil) ( Fig. 2D; Fig. S2A ). The same protective 150 effects were observed when the inhibitors were added alongside the virus and up to 4 151 hours post-inoculation (Fig. 2E) , and regardless of the inoculum (Fig. S2, B and C) . 152

For selected inhibitors, we quantified infectious viral titres in cell supernatants (Fig. 153 2F) and measured the proportion of cells showing cytopathic effects (CPE) as a result 154 of the infection (Fig. 2G) . While many untreated cells became infected and arranged 155 in clusters, both tunicamycin and NGI-1 provided the highest protection rates against 156 SARS-CoV-2 in Vero (97.3% and 97%) and HEK cells (92.3% and 92%) (Fig. 2 , A to ( Fig. 2I) suggests a possible accumulation of viral glycoproteins in the ER as a 169 consequence of the inhibition of the calnexin/calreticulin cycle (26) . Inhibition of the 170 Golgi a-mannosidases using DMJ and Swainsonine produced no effect in Vero cells 171 but did reduce HEK cell infections, resembling the phenotypes seen in siMGAT1 (Fig.  172 1). Differences in baseline N-glycosylation profiles between Vero and HEK cells ( Fig  173   S4A ; File S1 and S2) and expression of the Golgi's endo-a-1,2-mannosidase 174 (MANEA)(27) independent pathway may account for such variations. Cell viability 175 assays were run in parallel to rule out poor metabolism or toxicity as the main cause 176 of infection decrease (Fig. S2D) , although drug off-target effects may play a role at 177 high doses. Lastly, we investigated whether two inhibitors combined may increase 178 their potency (Fig. S2E) . While the combination of tunicamycin and NGI-1 did not 179 significantly improve their respective individual efficacies, simultaneous treatment of 180 NGI-1 with any a-glucosidase inhibitor promoted higher protection rates compared to 181 NGI-1 or a-glucosidase alone. Furthermore, some combinations of a-glucosidase 182 inhibitors were particularly efficacious (e.g., Miglustat combined with Miglitol) and 183 combinations with a-mannosidase inhibitors also resulted in augmented efficacies. 184

The corresponding changes in protein glycosylation upon drug treatment were 185 determined by HILIC-UPLC (Fig S3A and S4C ; Data S1). 186 187 We then hypothesized that virions assembled in cells with altered N-glycosylation may 188 present abnormal spike N-glycosylation profiles and consequently become less 189

infectious. As a model, we used virions produced in Vero E6 cells treated with 5 µM 190 NGI-1. This treatment was previously observed to greatly reduce the proportion of 191 infected cells while allowing the formation of fewer infective viral particles (Fig. 2) . 192

Supernatants from infected NGI-1-treated cells contained on average 392-fold less 193 infective viral particles than untreated cells (Fig. 3A) . However, quantification of total 194 viral RNA (i.e., infective and non-infective particles) showed only 82-fold reduction 195 ( Fig. 3B) . This imbalance between total and infective particles (4.8-fold) may account 196 for virions incapable of infecting host cells as a result of missing or expressing aberrant 197 protein N-glycans. To validate the hypothesis, supernatants were used to infect cells 198 normalizing the virus inoculum based on total viral RNA. Virions released by NGI-1-199 treated cells still produced lower infections (4.4-fold), evidencing the existence of a pre-treated with NGI-1 showed an even stronger reduction when inoculated with 202 virions produced in NGI-1-treated cells. To confirm that the absence surface N-glycans 203 renders viral particles non-infective, we incubated intact SARS-CoV-2 virions with 204 Peptide-N-Glycosidase F (PNGase F) prior to infection (Fig. 3, D to H) . PNGase F 205 removes all types of N-linked oligosaccharides from glycoproteins, except those with 206 core a1,3-fucose. Under this condition, the enzyme is only expected to cleave 207 accessible N-glycans from the surface exposed viral glycoproteins spike, membrane 208 (M) and envelope (E). Overall protein deglycosylation was confirmed by lectin blotting 209 ( Fig. S5A) , and by analyzing the mobility of spike and M proteins by western blotting 210 ( Fig. 3D) . Mock-treated (P-) and control (C) virions showed a full-length spike band 211 (S0; ~250 kDa) and four more of higher apparent molecular mass likely corresponding 212 to aggregates resistant to denaturing, multimeric or more glycosylated forms. In virions 213 treated with PNGase F (P+), all bands significantly downshifted due to the loss of N-214 glycans. In addition, two M bands were detected in control samples corresponding to 215 unglycosylated (~25 kDa) and glycosylated (~30 kDa) forms, with the latter collapsing 216 to ~25 kDa upon digestion. Remarkably, deglycosylated virions (P+) were unable to 217 infect host cells, while cells inoculated either with P-or C presented infection levels 218

comparable to those inoculated with non-purified supernatant virions (SN) (Fig. 3, F  219 to H). Quantification of total viral RNA (Fig. S5B) and infectious particles in cell 220 supernatants (Fig. S5C ) confirmed that P+ did not develop SARS-CoV-2 infection. 221

Cells inoculated with heat-inactivated PNGase F-treated virions (PIN) or co-inoculated 222 with PNGase F (PT0) produced normal infections. We then used liquid chromatography 223 coupled to high-resolution tandem mass spectrometry (LC-HR-MS/MS) to identify the 224 spike N-glycosylation sites whose glycans were removed by the enzyme. By looking 225 at the conversion of asparagine into aspartate after PNGase F deglycosylation, we 226 found five spike peptides containing seven modified sites (i.e., N234D, N282D, 227 N331D, N343D, N801D, N1158D and N1173D) ( Fig. 3E ; Data S2 to S8). Although 228 other sites could be deglycosylated, removal of the complex-type N-glycans on sites 229 N331 and N343 (both within the RBD) is likely to be the cause of P+ infection failure, 230 as suggested in previous studies (9, 10, 14) . Lastly, deglycosylation of cell surface 231 glycoproteins prior to virus inoculation did not affect the infection outcome ( Fig. 3H  232 and Fig. S5D) , suggesting that host surface N-glycans (i.e., susceptible to PNGase F In summary, we investigated the essentiality of host N-glycosylation pathway and 235 SARS-CoV-2 N-glycans in relation to infection. Our data suggest that inhibiting host 236 N-glycosylation does not prevent virus recognition and invasion in first place. Instead, 237 we propose that the consequent N-glycosylation alterations in newly synthesized viral 238 proteins negatively impact the production of new infective virions. Cells with altered N-239 glycosylation release fewer virions with missing or aberrant spike N-glycans that are 240 essential for invasion. Overall, altering host N-glycosylation leads to a reduction of the 241 spread of SARS-CoV-2 infection, and the earlier the pathway is halted the more 242 effective this reduction becomes (Fig. 4) . The evidence generated in this study allows 243 further research on developing ways to exploit N-glycosylation to treat Some of the inhibitors tested here (i.e., Miglustat, Miglitol, Acarbose and Celgosivir) 245 are drugs in trials or FDA-approved, used to treat unrelated human diseases and could 246 be considered for repurposing if found effective in trials, alone or in combination. 247 worldwide, is equally affected by glycosylation inhibitors. This brings hope for a 253 standalone therapy and may also maximise the efficacy of current vaccines, as 254 partially glycosylated viruses will be more vulnerable to neutralising anti-spike 255 antibodies(14). Importantly, approaches targeting essential N-glycans may offer an 256 advantage over protein-based ones as N-glycosylation is a more conserved post-257 translational modification less favourable to mutation. In fact, no mutations concerning 258 

Cell and SARS-CoV-2 culture Vero E6 cells (C1008; green African monkey kidney cells) were obtained from Public Health England and cultured in DMEM medium (Lonza) supplemented with 10% foetal bovine serum (FBS; Gibco) and 50 µg/mL gentamicin (Sigma) at 37°C and 5% CO2. HEK293 ACE-2 cells (lentiviral expression of human angiotensin-converting enzyme 2) were cultured in DMEM supplemented with 10% FBS, 1mM sodium pyruvate (Gibco) and 2 µg/mL puromycin (Invivogen) at 37°C and 5% CO2. Cells were regularly passaged (passage 2 to 30) by trypsinization when >80% confluence was reached. SARS-CoV-2 isolate SARS-CoV-2/human/Liverpool/REMRQ0001/20 20, isolated from naso-pharyngeal swab from a patient in March 2020, was passaged four times in Vero E6 cells (31). Experimental cells were infected by incubation with SARS-CoV-2 (passage 4 in Vero E6) supernatant containing 2 x 10 7 pfu/mL in DMEM 2% FBS for 30 minutes at 37°C and 5% CO2, at variable MOIs (see below). SARS-CoV-2 variants B.1.1.7, B.1.351 and P.1 were obtained from BEI Resources.

siRNA knockdowns A total of 2 x 10 5 Vero E6 or HEK293 ACE-2 cells were seeded 24 hours before transfection with one of the following siRNAs pools (Qiagen SMARTpool): siSTT3A (#GS3703), siSTT3B (#GS201595), siGANAB (#GS23193) or siMGAT1 (#GS84061). Double knockdown of STT3A and STT3B was performed by transfecting equal amounts of siSTT3A and siSTT3B pools. Nontargeting control (siNT) was obtained from Dharmacon. 4µL of 100µM siRNA pool were combined with 6µL Lipofectamine RNAiMax (Invitrogen) in 200µL Opti-MEM (Gibco) and incubated for 20 minutes at RT before being added dropwise to the cells. Cells were flushed out with fresh medium 4 hours after transfection. For siGANAB and siMGAT1, 2 hits of siRNA over a 120-hour incubation period were performed while for siSTT3A, siSTT3B and siSTT3A+siSTT3B, 3 hits of siRNA over a 168-hour period were needed. The day before optimum knockdown (96 hours for 2 hits, 144 hours for 3 hits), cells were trypsinized and 2 x 10 4 cells were seeded for each condition onto 96-well optical plates (Greiner) in quadruplicate and infected the following day. Infections were carried out by incubation with SARS- Plaque assay Vero E6 were cultured in DMEM 10% FBS in 24-well plates and allowed to reach confluency overnight. Cells were incubated with 0.1 mL serially diluted supernatant containing SARS-CoV-2 for 30 minutes at 37°C and 5% CO2 before being left in 1.5mL overlay (DMEM, 2% FBS, 1.2% cellulose microcrystalline (Sigma)) at 37°C and 5% CO2 for 72 hours. Cells were fixed in formaldehyde for 30 minutes, washed and stained with 0.1% crystal violet 20% ethanol solution for manual plaque counting.

RT-qPCR RNA quantification Total RNA was extracted from supernatants of SARS-CoV-2-infected Vero E6 cells using the RNeasy kit (Qiagen) following the manufacturer's protocol. 4µL purified RNA were subsequently used for RT-qPCR reaction using the Luna Universal One-Step RT-qPCR kit (New England Biolabs) and 0.4µM of each primer: CoV2-N-F (CACATTGGCACCCGCAATC) and CoV2-N-R (GAGGAACGAGAAGAGGCTTGAC). Reactions were set and analyzed in an Agilent Mx3005P machine as follows: 55°C for 10 minutes, 95°C for 1 minute, 40 cycles of 95°C for 10 seconds followed by 60°C for 30 seconds; with final melting curve.

Immunofluorescence assay Cells cultured in optical plates were fixed in 4% formaldehyde (Pierce) for 30 minutes at RT, washed in PBS and permeabilized in 0.5% saponin for 10 minutes. Cells were then blocked in 1% bovine serum albumin (BSA) PBS for 45 minutes and further incubated in blocking solution containing anti-SARS-CoV-2 spike protein subunit 2 (Abcam) 1:1000 dilution for 1 hour at 37°C. Blocking solution containing DAPI 1µg/mL and Alexa Fluor 488 Plus-conjugated anti-mouse IgG (Thermofisher) was then incubated for 1 hour at RT. Cells were washed and left in PBS for imaging. Imaging was carried out using a Zeiss LSM800 confocal laser scanning microscope by tile-scanning entire plates conserving identical settings between comparable samples. Images were analyzed using Fiji (ImageJ) by thresholding to select for true signal and measuring relative cell area coverage in DAPI channel (total number of cells) and anti-spike area or mean fluorescence intensity (infected cells). Infection rates given as normalized infected area (anti-spike-positive) over total cell area (DAPI).

PNGase F deglycosylation of intact SARS-CoV-2 virions 2mL SARS-CoV-2 P4 supernatant containing 2 x 10 7 pfu/mL was purified using an Amicon Ultra column (MWCO 100kDa; Merck) by centrifugation and washing in PBS at 2,000 x g. 40 µL purified supernatant were combined with 2,500 units recombinant glycerol-free PNGase F and Glycobuffer 2 (New England Biolabs) following the manufacturer's protocol for non-denaturing digestion and incubated at 37°C for 5 hours. Parallel controls included incubation of purified virions with or without PNGase F and Glycobuffer, incubation with heat-inactivated (75°C for 10 minutes) PNGase F, and incubation with PNGase F and Glycobuffer during virus inoculation of host cells for 30 minutes. After incubation, samples were either directly used for infection or combined with RIPA buffer supplemented with protease inhibitors to generate lysates for blotting. Alternatively, Vero E6 cells were pre-incubated with or without 100,000 units/mL PNGase F in serum-free OptiMEM for 5 hours at 37°C and 5% CO2, before being either inoculated with SARS-CoV-2 or surface-biotinylated. To biotinylate surface proteins, cells were washed in PBS pH=8, incubated with EZ-link NHS-biotin (Thermofisher) 2.5mM for 30 minutes on ice, washed in PBS 100mM glycine and lysed in RIPA buffer and protease inhibitors as above.

Western, lectin and streptavidin blotting siRNA cell lysates were obtained at either 120-hours (2 hits) or 168-hours (3 hits) by washing cells in cold PBS and incubation in RIPA buffer with 1% phosphatase and protease inhibitor cocktail (ThermoScientific). Protein concentration was determined using Precision Red (Cytoskeleton) and 60µg of protein were separated using 4-15% SDS-PAGE gels and transferred onto nitrocellulose membrane. Alternatively, virion lysates were run in 4-12% SDS-PAGE and dry-transferred onto PVDF membranes. Membranes were blocked in either 5% milk or 2% BSA in Tris-buffered saline or PBS, 0.1% Tween-20 (TBS-T) for 30 minutes and incubated with their corresponding primary antibodies at 4°C overnight. Primary antibodies used: anti-STT3A (HPA030735, Cambridge Bioscience), anti-STT3B (A15574, Universal Biologicals), anti-GANAB (A13851, Universal Biologicals), anti-MGAT1 (CSB-PA013773ESR1Hu, 2B Scientific), anti-GAPDH (10494-1-AP, ProteinTech), anti-spike S2 (Abcam) and anti-M (. Blots were then incubated with anti-rabbit IgG conjugated with horseradish peroxidase (Cell Signalling) or Alexa Fluor Plus 800 (Thermofisher), or anti-mouse IgG conjugated with Alexa Fluor Plus 680 (ThermoFisher) for 1 hour. Blots were visualized on a BioRad ChemiDoc TM Touch Gel Imaging System using enhanced chemiluminescence substrate (for horse radish peroxidase secondary) or on a LI-COR Odyssey Fc (for fluorescence). Virion lysate blots were then incubated with 5 µg/mL concanavalin A FITCconjugated in 1% BSA 0.05% Tween-20 PBS for 30 minutes. GAPDH or nigrosine staining were utilized as loading control. Streptavidin blots were incubated in streptavidin-Alexa Fluor 555 (Thermofisher) 5µg/mL in PBS 0.1% Tween20, 0.02% SDS for 30 minutes at RT. Lectin and streptavidin blots were imaged using a Thermofisher iBright FL1500 system.

Either siRNA-or inhibitor-treated cells were harvested by trypsinization, washed in cold PBS, manually counted and snap frozen. A total of 2x10 6 (Vero E6) or 3x10 6 (HEK293 ACE-2 ) cells were used for the analyses, alongside Ludger IgG as positive and water as negative controls for insolution N-glycan release, labelling and clean-up. Samples were denatured at 100°C with SDS and dithiothreitol before incubation overnight with PNGase F in NP-40 buffered solution. The released glycans were then converted to aldoses with 0.1% formic acid, filtered through a protein binding membrane and dried. N-glycans were then labelled with procainamide, cleaned up in water, dried and reconstituted in water. Samples were analysed by HILIC-UPLC using an ACQUITY UPLC BEH-Glycan 1.7 mm, 2.1x150mm column at 40°C on a Thermo Scientific UltiMate 3000 UPLC with a fluorescence detector (excitation = 310 nm; emission = 370nm) controlled by HyStar software v3.2. Gradient conditions were: 0 to 53.5 min, 24 to 49 % Buffer (A) at a flow rate of 0.4 mL/min; 53.5 to 55.5 min, 49 to 100% A, 0.4 to 0.2 mL/ml; 55.5 to 57.5 min, 100% A at 0.2 mL/min; 57.5 to 59.5 min, 100 to 24% A at 0.2 mL/min; 59.5 to 65.5 min, 24% A at 0.2 mL/min; 65.5 to 66.5 min, 24% A from 0.2 to 0.4 mL/min; 66.5 to 70 min 24% A at 0.4 mL/min. Buffer A was 50 mM ammonium formate; Buffer B was acetonitrile (Acetonitrile 190 far UV/gradient quality). Samples were injected in 25% aqueous/75% acetonitrile; injection volume 25 μL. Ludger procainamide labelled glucose homopolymer, A2 & A3 mix, FA2 mix and Man mix were used as standard and as external calibration for GU allocation. All standards were run in the same injection volume and conditions as the samples. Thermo Scientific Chromeleon software v7.2.1 was used to allocate GU values to peaks. When software did not split peaks that were not fully resolved, areas were merged together across peaks. Glycan analyses were performed by Ludger Ltd (32-34).

Trypsin digestion for proteomic analysis Purified virions were subjected to PNGase F treatment (P+; sample#3) or heat-inactivated PNGase F treatment (PIN; sample#4) as described above. The positive controls (for viral proteins) included purified virions (C; sample#1) and PNGase F mock-treatment of purified virions (P-; sample#2). The negative controls (devoid of viral proteins) included DMEM 2% FBS (sample#5) and Vero E6 cell culture conditioned supernatant or secretome in DMEM 2% FBS (sample#6), both purified by size exclusion as described above. Samples were incubated in 80% ice-cold acetone for 1 hour at -20°C for protein precipitation, spun down at 14,000xg for 15 min and pellets were air-dried. Peptides were obtained from the via FASP Protein Digestion Kit (#ab270519, Abcam, Cambridge, MA), using trypsin (Proteomics Grade, #T6567, Sigma-Aldrich, St. Louis, MO). Lyophilized intact protein samples #1-6 (141-478 µg protein) were redissolved in 200 µl 100 mM Tris-HCl pH 7.0, containing 8M urea (urea sample solution, USS). Protein digestion was performed with 100 µl of each sample and transferred to a 1.5mL microtube containing 200 µL USS. 100 mM DLdithiothreitol (catalog #D0632, Sigma-Aldrich) was added to reduce protein disulfide bonds and achieve complete protein unfolding. Samples were vortexed for 30 s and then kept swaying on a nutating mixer (Nutator Mixer Model 117, TCS Scientific Corp.) for 45 min at RT prior to proteome extract digestion protocol. Samples were transferred to a 30-kDa Spin Filter (FASP Kit), previously assembled on a collection tube and centrifuged at 14,000 x g for 15 min at RT. 200 µl USS was added to each Spin Filter and further centrifuged for 15 min. Flow-through from the collection tube was discarded and 100 µl of fresh prepared 10 mM iodoacetamide, resuspended in USS, was added to the Spin Filter and samples were subsequently subjected to incubation without mixing for 20 min in the dark at RT for alkylation. After incubation, the Spin Filters were centrifuged at 14,000 x g for 10 min at RT. 100 µl of USS was added to the Spin Filter and samples were centrifuged at 14,000 x g for 15 minutes. This step was repeated twice. Flow-through was again discarded. 100 µL 50 mM ammonium bicarbonate solution was added to the Spin Filter and sample was centrifuged at 14,000 x g for 15 min, at RT. This step was repeated twice. After USS removal by ammonium bicarbonate, Spin Filter containing protein sample was transferred to a new collection tube and 100 µL trypsin was added to the Spin Filter, at an enzyme-to-protein ratio of 1:50. Evaporation was prevented by wrapping the top of the tubes with parafilm. The Spin Filter was incubated at 37°C for 16 h without mixing. 200 µL LC-MS grade 0.1% formic acid was added to stop the proteolysis, and each sample was then centrifuged at 14,000 x g for 10 min to obtain the filtrate containing the tryptic peptides. The collection tubes containing the peptides were dried down in a Speedvac concentrator (Savant, Thermo Fisher Scientific) and the volume was adjusted with LC-MS grade 0.1% formic acid (Thermo Fisher Scientific) to a final concentration of 1 µg/µL of tryptic peptides prior to liquid chromatography-high resolution-tandem mass spectrometry (LC-HR-MS/MS) analysis.

The equivalent of 1 µg microgram of protein digest from each sample (samples #1-6), as measured by NanoDrop One/One Microvolume UV-Vis Spectrophotometer (Thermo Fisher Scientific) was loaded onto a 50-cm µPAC capLC column (PharmaFluidics, Ghent, Belgium) separated by a Dionex Ultimate 3000 RSLCnano (Thermo Fisher Scientific) with 99% solvent A (100% water, 0.1% formic acid) and 1% solvent B (90% acetonitrile, 0.1% formic acid), at a flow rate of 750 nL/min for 5 min. The flow rate was decreased to 300 nL/min at 5.1 min, to start the elution gradient. Solvent B was increased to 22% over 64.9 min, then to 45% solvent B over 15 min. The gradient was increased to 95% solvent B over 5 min and maintained at a plateau for an additional 9 min. The gradient sharply decreased to 1% solvent B over 1 min for equilibration with a flow rate at 750 nL/min, maintained for 10 min, thus ending the 120-min sample runtime. Eluted peptides were ionized with a µPAC Flex iON connect (PharmaFluidics, Ghent, Belgium) attached to a Nanospray Flex Ion Source (Thermo Fisher Scientific) equipped with a nanoESI emitter (FOSSILIONTECH, Madrid, Spain) . Data was acquired using a Q Exactive Plus Hybrid Quadrupole-Orbitrap Mass Spectrometer (QE Plus, Thermo Fisher Scientific). The QE Plus analysis parameters were as follows: full MS resolution at 70,000; AGC target of 1e 6 ; and scan from 350 to 1400 m/z range. Top 10 data-dependent MS 2 parameters were set to 17,500 resolution, ACG target of 1e 5 , (N)CE: 27, charged exclusion at unassigned, +1, +6-8, +>8 with mass exclusion set to ON. Samples #5 and #6 were run previously to generate an exclusion list. The top 200 ions were collected every 5 min (in a total run of 120 min) to generate a 4,800-ion exclusion list prior to sample injection containing virions (samples#1-4). All samples were run in technical duplicate.

Bioinformatic analysis of proteomic data Proteomic data analysis was initially performed using Proteome Discoverer (PD) v2.5.0.400 (Thermo Fisher Scientific), with an estimated false discovery rate (FDR) of 1%. Common contaminants such as trypsin autolysis fragments, human keratins, and protein lab standards, were included as well as in-house contaminants, which may be found in the cRAP contaminant database (35). SARS-CoV-2 database (36,795 entries) was downloaded in FASTA format on May 18, 2021, from UniProtKB (http://www.uniprot.org/). Additionally, a second SARS-CoV-2 database was added to include the modification of asparagine (N) to aspartic acid (D), resulting from PNGase F treatment (36), to illustrate the conserved N-glycosylation sequon N-X-S/T, where X is any amino acid except proline. The following parameters were used in the PD analysis: HCD MS/MS; fully tryptic peptides only; up to 2 missed cleavages; parent-ion mass tolerance of 10 ppm (monoisotopic); and fragment mass tolerance of 0.6 Da (in Sequest) and 0.02 Da (in PD 2.1.1.21) (monoisotopic). A filter of two-high confidence peptides per protein were applied for identifications. PD dataset was further processed through Scaffold Q+ 4.8.2 (Proteome Software, Portland, OR) to obtain the protein quantification and further analysis of the MS/MS spectra. A protein threshold of 95%, peptide threshold of 90%, and a minimum of 1 peptide were used for protein validation by manual inspection of each MS/MS spectrum. Proteomics raw data uploaded into PRIDE-EMBL-EBI, internal ID#507100.

Glycan analyses confirm alterations in protein N-glycosylation after genetic and chemical inhibition To corroborate changes in protein glycosylation upon siRNA or drug treatment, we compared the profiles of procainamide-labeled N-glycans from treated and untreated cells using HILIC-UPLC (Fig S3 and S4 ; Data S1). Both cell types appear to express similar glycan profiles, although some species differ in abundance. For example, while the major species in untreated HEK cells were Man5GlcNAc2 (M5, peak 19), M6 (peak 30), M7/FA2G1S1 (peak 41), M8 (peak 53), and M9/A3G3S3 (peak 62), Vero cells appear to produce mainly oligomannose glycans and less of the hybrid-and complex-type ones (Fig S4A) . When STT3-A was knocked out in Vero cells only a (Data S2). Based on the normalized total spectra of each sample, N proteins were the major proteins found in all virion-containing samples, followed by spike and M proteins were of low abundance (Data S3). To locate the D residues resulting from PNGase F removal of N-glycans from asparagine residues, we used an in-house script that converted the N-to-D in all SARS CoV-2 proteins deposited in the UniProtKB database, including the 22 potential N-glycosylation sites in the spike protein. Data S4 shows all the identified spike proteins in the four samples. We included the complete sequence of the spike proteins highlighting the peptides identified by LC-HR-MS/MS to facilitate the visualization of the location of these peptides in each protein sequence and the protein sequence coverage. While no deglycosylated peptides were detected in positive control samples (purified virions alone and mock-treated purified virions) (Data S5), in purified virions treated with PNGase F we detected identified five peptides with N-to-D conversion (DLPQGFSALEPLVDLPIGIDITR, YNEDGTITDAVDcALDPLSETK, FPDITNLcPFGEVFD ATR, TPPIKDFGGFDFSQILPDPSKPSK, and DHTSPDVDLGDISGIDASVVNIQK) (Data S5). The MS/MS fragmentation and fragment-ion assignments of these peptides are shown in Data S8. Of particular interest, peptide FPDITNLcPFGEVFDATR (residues 329-346) is located within the spike RBD, which is essential for the virus binding to the ACE-2 human receptor. A BLASTp analysis of this peptide sequence showed that in all 5,000 spike protein sequences analyzed (maximum number of sequences allowed by BLASTp search), the sequence is fully conserved, strongly indicating that these two N-glycans could be essential for interaction with ACE2. Moreover, we found six peptide sequences in the purified virion sample treated with PNGase F (sample # 3) in which the N residue had not been substituted by D, thus indicating some S protein N-glycosylation sites remain unglycosylated (Data S4). It is important to underscore that PNGase F does not cleave complex N-glycans with a fucose residue a1-3-linked to the reducing GlcNAc linked to the N residue (36, 37). This indicates that most likely the two cleaved complex-type Nglycans on N331 and N343 are modified with an a1-6-linked fucose residue. Finally, since part of the M protein appears to be N-glycosylated (Fig. 3D) we also searched for any potential N-to-D conversion after PNGase F treatment. Intriguingly, we found that all tryptic peptide sequences identified in M were located near the C-terminus of the protein, but we failed to find peptide sequences indicative of an N-to-D conversion (Data S7). Of note, the only potential Nglycosylation sequon found in 763 M protein sequences analyzed through BLASTp and multiple sequence alignment was located at the N-terminus within an apparent ER signal peptide (SP) (e.g., MSDSNGTITV..., MADSNGTITV…), which could not be confirmed by SignalP 4.1 analysis (http://www.cbs.dtu.dk/services/SignalP-4.1/). Therefore, the shift in migration of M following Nglycan removal by PNGase F (Fig. 3D) can only be explained if the non-canonical N-terminus SP of M proteins is not cleaved after protein synthesis in the ER and the N-glycan is eventually attached to it. This suggests that the N-terminus tryptic peptide containing the N-glycan is either further processed (e.g. cleaved or modified with another post-translational modification) or was somewhat altered during sample preparation.

. siRNA knockdown validation. Western blotting of lysates from either Vero E6 or HEK293 ACE-2 cells treated with siRNA targeting glycosylation genes (i.e., STT3-A, STT3-B, GANAB and MGAT1). Lysates probed with specific antibodies against the targeted protein; non-targeted control (siNT). Estimated apparent molecular weights annotated. GAPDH was used as loading control. . Peaks identified with numbers; colours represent intensity decrease (blue) or increase (red) compared to the control. Bar graphs represent intensity fold change of the sum of all peaks (gray) and individual peaks with the greatest decrease (blue) or increase (red) in intensity compared to the control. The procainamide molecule linked to each glycan is omitted in this figure. 

Genomic characterisation and epidemiology of 2019 novel coronavirus

On the other hand, HEK siRNA cells presented N-glycan profile modifications slightly different to those seen in Vero cells (Fig S4B). siSTT3-A was the only STT3-targeting treatment that significantly reduced glycan levels globally (43%), since siSTT3A+B barely produced any effect (7% reduction). siGANAB and siMGAT1 led to increases of 7.5% and 45.1%, respectively, the latter mainly due to a more pronounced accumulation of M5 compared to that in Vero cells. When either Vero or HEK cells were incubated with glycosylation inhibitors, abnormal N-glycosylation patterns were observed compared with that from untreated cells (Fig S3 and S4)

In addition, NN-DNJ augmented the abundance of a broad range of peaks, including 9

As negative controls for the N-to-D conversion, we used purified virions treated with heat-inactivated PNGase F, as well as purified virions alone or subjected to PNGase F mock treatment. Following treatment, samples were subjected to trypsin digestion and the resulting peptides were analyzed by LC-HR-MS/MS using a high-resolution 50-cm µPAC capLC C18 column directly coupled to the QE Plus MS. The identified proteins and peptides from SARS-CoV-2 (samples #1-4) following PD and

The authors declare no competing interests.